2Williams MP,Pounder RE. The pharmacology of rabeprazole[J]. Ali-ment Pharmacol Ther, 2009,13(Suppl 3):3-10.
3Yukiko Mine, Takashi Yoshikawa,Seiko Oku’et al. Comparison of Ef-fect of Mosapride Citrate and Existing 5—HT4 Receptor Agonists onGastrointestinal Motilityln Vivo and In Vitro[J]. JPET, 2007 ,283(3):1000-1008.
3Trudgill NJ,Hussain FN,Moustafa M,et al.The effect of cholecysto kinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease.Aliment Pharmacol Ther,2001,15:1357-1364.
4Spechler S J,Lee E,Ahnen D,et al.Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease:follow-up of a randomized controlled trial.JAMA,2001,285:2331-2338.
5Annese V,Caletti G,Cipolletta L,et al.Endoscopic treatment of gastroesophageal reflux disease.Endoscopy,2005,37:470-478.
6Thomson AB.The dyspepsia alphabet:DU,GU,GERD,NERD,NUD/FD and UD.Can J Gastroenterol,2001,15:49-55.
7Fass R,Ofman JJ.Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am J Gastroenterol,2002,97:1901-1909.
8Carlsson R,Dent J,Watt R,et al.Gastro-oesophageal reflux disease in primary care:an in ternational study of different treatment strategies with omeprazole.Eur J Gastroenterol Hepatol,1998,10:119-124.
9Fass R.Gastroesophageal reflux disease revisited.Gastroenterol Clin North Am,2002,31 (suppl 4):S1-10.
